In a report published Wednesday, Bank of America analyst Steve Byrne reinstated coverage on Incyte INCY with a Buy rating and $84.00 price target.
In the report, Bank of America noted, “We are reinstating coverage of Incyte (INCY) with a Buy rating and $84 PO. The company's single commercial product Jakafi (ruxolitinib, oral blocker of JAK1/JAK2) accounts for half of our valuation, driven by double digit revenue growth that could accelerate in early 2015 with approval in a new indication. The balance of our PO is from INCY's pipeline, largely driven by the significant long-term potential of the company's IDO inhibitor and pipeline of JAK inhibitors as broad oncology platforms as both interrupt tumor cells' ability to evade the immune system (via T-cell inhibition and tumor-induced inflammation, respectively). While still early in development, the potential to serve as combo backbone drugs is compelling.”
Incyte closed on Tuesday at $68.37.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in